Resected Stage
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (NCT05040568) | M.D. Anderson Cancer Center | 2022-02-28 |
Track Resected Stage automatically
Every clearance here is in the API, with alerts when new ones post.